Paper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803
Oral and Poster Abstracts 731. Clinical Autologous Transplantation: Results: Poster I Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD1, Antje Hoering, PhD2, Parameswaran Hari, MBBS, MD3, Rachael Sexton, PhD2* and Robert Z. Orlowski, MD, PhD41City of Hope Medical Center, Duarte, CA2SWOG Statistical Center, Seattle,…
